S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
NASDAQ:LIFE

aTyr Pharma Competitors

$4.35
-0.21 (-4.61 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.25
Now: $4.35
$4.63
50-Day Range
$3.53
MA: $4.74
$8.06
52-Week Range
$2.13
Now: $4.35
$8.33
Volume231,968 shs
Average Volume1.25 million shs
Market Capitalization$44.30 million
P/E RatioN/A
Dividend YieldN/A
Beta2.17

Competitors

aTyr Pharma (NASDAQ:LIFE) Vs. TMO, ILMN, A, MTD, BIO, and WAT

Should you be buying LIFE stock or one of its competitors? Companies in the sub-industry of "life sciences tools & services" are considered alternatives and competitors to aTyr Pharma, including Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), and Waters (WAT).

Thermo Fisher Scientific (NYSE:TMO) and aTyr Pharma (NASDAQ:LIFE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

87.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 55.8% of aTyr Pharma shares are owned by institutional investors. 0.4% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 9.4% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Thermo Fisher Scientific and aTyr Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Thermo Fisher Scientific17.12%21.35%10.55%
aTyr Pharma-202.02%-52.75%-38.40%

Analyst Ratings

This is a summary of recent recommendations for Thermo Fisher Scientific and aTyr Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Thermo Fisher Scientific041502.79
aTyr Pharma00303.00

Thermo Fisher Scientific presently has a consensus price target of $529.6667, suggesting a potential upside of 17.68%. aTyr Pharma has a consensus price target of $12.00, suggesting a potential upside of 175.86%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Thermo Fisher Scientific.

Volatility and Risk

Thermo Fisher Scientific has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.

Valuation and Earnings

This table compares Thermo Fisher Scientific and aTyr Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$25.54 billion6.98$3.70 billion$12.3536.44
aTyr Pharma$420,000.00105.49$-23,600,000.00($7.03)-0.62

Thermo Fisher Scientific has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Thermo Fisher Scientific beats aTyr Pharma on 9 of the 14 factors compared between the two stocks.

Illumina (NASDAQ:ILMN) and aTyr Pharma (NASDAQ:LIFE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

90.0% of Illumina shares are owned by institutional investors. Comparatively, 55.8% of aTyr Pharma shares are owned by institutional investors. 0.4% of Illumina shares are owned by company insiders. Comparatively, 9.4% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Illumina and aTyr Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Illumina19.70%15.93%10.09%
aTyr Pharma-202.02%-52.75%-38.40%

Analyst Ratings

This is a summary of recent recommendations for Illumina and aTyr Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Illumina38702.22
aTyr Pharma00303.00

Illumina presently has a consensus price target of $365.3158, suggesting a potential downside of 16.86%. aTyr Pharma has a consensus price target of $12.00, suggesting a potential upside of 175.86%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Illumina.

Volatility and Risk

Illumina has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.

Valuation and Earnings

This table compares Illumina and aTyr Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Illumina$3.54 billion18.09$1.00 billion$6.5766.88
aTyr Pharma$420,000.00105.49$-23,600,000.00($7.03)-0.62

Illumina has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats aTyr Pharma on 9 of the 14 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and aTyr Pharma (NASDAQ:LIFE) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

55.8% of aTyr Pharma shares are owned by institutional investors. 9.4% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Agilent Technologies and aTyr Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agilent Technologies13.47%21.02%10.73%
aTyr Pharma-202.02%-52.75%-38.40%

Analyst Ratings

This is a summary of recent recommendations for Agilent Technologies and aTyr Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agilent Technologies0101602.62
aTyr Pharma00303.00

Agilent Technologies presently has a consensus price target of $100.4619, suggesting a potential downside of 17.70%. aTyr Pharma has a consensus price target of $12.00, suggesting a potential upside of 175.86%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Agilent Technologies.

Volatility and Risk

Agilent Technologies has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.

Valuation and Earnings

This table compares Agilent Technologies and aTyr Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agilent Technologies$5.34 billion6.98$719 million$3.2837.22
aTyr Pharma$420,000.00105.49$-23,600,000.00($7.03)-0.62

Agilent Technologies has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Agilent Technologies beats aTyr Pharma on 8 of the 14 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and aTyr Pharma (NASDAQ:LIFE) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Mettler-Toledo International and aTyr Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$3.01 billion8.68$561.11 million$22.7749.01
aTyr Pharma$420,000.00105.49$-23,600,000.00($7.03)-0.62

Mettler-Toledo International has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mettler-Toledo International and aTyr Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mettler-Toledo International19.36%144.89%21.11%
aTyr Pharma-202.02%-52.75%-38.40%

Institutional and Insider Ownership

93.2% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 55.8% of aTyr Pharma shares are owned by institutional investors. 3.2% of Mettler-Toledo International shares are owned by company insiders. Comparatively, 9.4% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Mettler-Toledo International has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Mettler-Toledo International and aTyr Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mettler-Toledo International47101.75
aTyr Pharma00303.00

Mettler-Toledo International presently has a consensus price target of $868.0833, suggesting a potential downside of 22.22%. aTyr Pharma has a consensus price target of $12.00, suggesting a potential upside of 175.86%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Mettler-Toledo International.

Summary

Mettler-Toledo International beats aTyr Pharma on 8 of the 14 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and aTyr Pharma (NASDAQ:LIFE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Bio-Rad Laboratories and aTyr Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.31 billion7.54$1.76 billion$7.0682.79
aTyr Pharma$420,000.00105.49$-23,600,000.00($7.03)-0.62

Bio-Rad Laboratories has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bio-Rad Laboratories and aTyr Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories147.91%3.77%2.74%
aTyr Pharma-202.02%-52.75%-38.40%

Institutional & Insider Ownership

63.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 55.8% of aTyr Pharma shares are owned by institutional investors. 27.5% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 9.4% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Bio-Rad Laboratories has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Bio-Rad Laboratories and aTyr Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories00403.00
aTyr Pharma00303.00

Bio-Rad Laboratories presently has a consensus price target of $646.00, suggesting a potential upside of 10.52%. aTyr Pharma has a consensus price target of $12.00, suggesting a potential upside of 175.86%. Given aTyr Pharma's higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Bio-Rad Laboratories.

Summary

Bio-Rad Laboratories beats aTyr Pharma on 10 of the 13 factors compared between the two stocks.

Waters (NYSE:WAT) and aTyr Pharma (NASDAQ:LIFE) are both computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Waters and aTyr Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$2.41 billion7.06$592.20 million$8.9930.46
aTyr Pharma$420,000.00105.49$-23,600,000.00($7.03)-0.62

Waters has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Waters and aTyr Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Waters22.61%-349.31%21.11%
aTyr Pharma-202.02%-52.75%-38.40%

Institutional & Insider Ownership

91.8% of Waters shares are owned by institutional investors. Comparatively, 55.8% of aTyr Pharma shares are owned by institutional investors. 1.5% of Waters shares are owned by company insiders. Comparatively, 9.4% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Waters has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Waters and aTyr Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Waters58101.71
aTyr Pharma00303.00

Waters presently has a consensus price target of $219.4545, suggesting a potential downside of 19.87%. aTyr Pharma has a consensus price target of $12.00, suggesting a potential upside of 175.86%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Waters.


aTyr Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.3$450.08-0.3%$178.38 billion$25.54 billion36.89Dividend Increase
Illumina logo
ILMN
Illumina
1.7$439.41-1.5%$64.11 billion$3.54 billion101.95
Agilent Technologies logo
A
Agilent Technologies
1.8$122.07-0.0%$37.28 billion$5.34 billion53.07Buyback Announcement
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,116.05-0.6%$26.12 billion$3.01 billion46.95Decrease in Short Interest
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$584.50-0.4%$17.44 billion$2.31 billion5.00
Waters logo
WAT
Waters
1.5$273.88-1.6%$16.99 billion$2.41 billion34.11Decrease in Short Interest
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.5$286.14-2.1%$14.24 billion$2.62 billion47.69Analyst Upgrade
Insider Selling
News Coverage
PerkinElmer logo
PKI
PerkinElmer
1.9$126.09-0.1%$14.12 billion$2.88 billion34.26
Bio-Techne logo
TECH
Bio-Techne
1.8$361.69-0.9%$14.03 billion$738.69 million57.87Analyst Upgrade
Bruker logo
BRKR
Bruker
2.1$60.98-3.0%$9.34 billion$2.07 billion59.78Decrease in Short Interest
News Coverage
Gap Down
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$30.57-2.0%$5.51 billion$90.89 million-109.17Insider Selling
Decrease in Short Interest
Gap Down
Luminex logo
LMNX
Luminex
1.8$32.52-1.4%$1.51 billion$334.64 million83.39
Fluidigm logo
FLDM
Fluidigm
1.8$4.60-4.8%$340.95 million$117.24 million-6.87Gap Down
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.4$4.39-1.4%$171.11 million$116.18 million-24.39Gap Up
This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.